Core Scientific (CORZ) EBT Margin (2021 - 2026)

Core Scientific has disclosed EBT Margin across 6 years of filings, most recently posting 300.74% for Q1 2026.

• EBT Margin for Q1 2026 came in at 300.74%, down 102562.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 341.4% (down 8065.0% YoY), and the FY2025 annual result was 90.29%, up 19111.0% from the prior year.
• EBT Margin came in at 300.74% for Q1 2026 at Core Scientific, down from 270.87% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 724.87% in Q1 2025 to a low of 1191.23% in Q2 2025.
• The 5-year median for EBT Margin is 220.13% (2022), against an average of 208.33%.
• Across the five-year window, EBT Margin jumped 60725 bps in 2025 and sank 102562 bps in 2026, its largest moves.
• Core Scientific's EBT Margin stood at 376.36% in 2022, then soared by 63 bps to 137.64% in 2023, then slumped by 123 bps to 306.32% in 2024, then surged by 188 bps to 270.87% in 2025, then tumbled by 211 bps to 300.74% in 2026.
• The last three EBT Margin figures came in at 300.74% (Q1 2026), 270.87% (Q4 2025), and 177.43% (Q3 2025), per Business Quant data.